-
Filipin III for Cholesterol Detection in Macrophages
2026-09-19
Filipin III converts membrane cholesterol biology into a spatially resolved assay, helping researchers distinguish cholesterol redistribution from bulk lipid accumulation in macrophage models. This workflow connects membrane imaging with SOAT1, lipophagy, and pulmonary fibrosis research while emphasizing controls for signal quenching, reagent instability, and cholesteryl ester misinterpretation.
-
Vorinostat and the Next Era of Translational Epigenetics
2026-09-18
Vorinostat (SAHA, MK0683) is more than a cytotoxicity reagent: it is a mechanistic tool for connecting histone acetylation, gene regulation, mitochondrial apoptosis, and translational response heterogeneity. This article shows how researchers can pair HDAC inhibition with dynamic enzyme-activity measurements, informed by recent HO-1 probe research, to build more decision-ready oncology workflows.
-
Cy3 Rabbit Anti-Goat IgG (H+L) Antibody
2026-09-18
Cy3 Rabbit Anti-Goat IgG (H+L) Antibody provides fluorescence-based detection of goat IgG in ICC/IF, tissue staining, flow cytometry, and ELISA workflows. It should be used with goat immunoglobulin-based primary or detection antibodies, not treated as a universal secondary for other host species or as a replacement for enzyme-conjugated reagents.
-
(S)-(+)-Ibuprofen: From Synthesis to Assay Design
2026-09-17
Explore how (S)-(+)-Ibuprofen functions as a stereochemically defined COX inhibitor and how its synthesis, mechanism, handling, and dose selection inform robust inflammation and pain research assays.
-
CHK1 Inhibition in Breast Cancer: ER/PR-Specific Effects
2026-09-17
The 2020 International Journal of Biological Sciences study shows that CHK1 inhibition has different therapeutic consequences in breast cancer depending on ER and PR status. Its mechanistic analysis connects receptor-defined biology with ADR sensitization in ER−/PR−/HER2− disease and single-agent activity in ER+/PR+/HER2− tumors, providing a framework for more selective targeted-therapy design.
-
Meropenem Trihydrate in Resistance Phenotyping
2026-09-16
Meropenem trihydrate is more than a broad-spectrum carbapenem antibiotic: it is a practical anchor for connecting antibacterial assays with metabolomics-based resistance phenotyping. This article translates recent LC-MS/MS evidence into clearer decisions for microbiology, infection-model, and antibiotic resistance studies.
-
From Redox Biosensing to Reliable mCherry Readouts
2026-09-16
A translational guide to using Cap 1, 5mCTP, and ψUTP-modified mCherry mRNA as a reproducible fluorescent reporter, informed by lessons from genetically encoded NADH/NAD+ biosensing.
-
APEX2 Supports TERT Expression in Human Stem Cells
2026-09-15
This preprint identifies APEX2 as a DNA repair factor required for efficient TERT expression and telomerase activity in human embryonic stem cells and a melanoma model. Its combination of knockdown, RNA-seq, and chromatin immunoprecipitation suggests that repair of damage-prone repetitive DNA within the TERT locus may connect genome maintenance with gene regulation.
-
Meropenem Trihydrate: Readouts Beyond MIC
2026-09-15
Meropenem trihydrate can do more than support susceptibility testing: it provides a defined antibacterial perturbation for connecting growth phenotypes with microbial metabolism. This guide translates recent carbapenem-resistance metabolomics into practical assay decisions, controls, and research applications.
-
Lysosomal β-Galactosidase Staining Kit for HNSCC
2026-09-14
Use K2181 to visualize lysosomal acidic β-galactosidase in HNSCC cells and tissue sections while keeping senescence claims analytically disciplined. Its chromogenic readout, polystyrene compatibility, and defined controls make it a practical companion assay for cisplatin-resistance studies.
-
Topotecan HCl: Applied Cancer Assay Workflows
2026-09-14
Build more informative cancer drug assays with Topotecan HCl, a topoisomerase 1 inhibitor suited to DNA-damage, viability, sphere-formation, and tumor-model studies. The workflow separates growth inhibition from actual cell killing so lung carcinoma, prostate, and breast cancer responses are not reduced to a single misleading endpoint.
-
Methotrexate Beyond DHFR: Translational Design Rules
2026-09-13
Methotrexate is more than a DHFR inhibitor: its intracellular polyglutamates, cell-cycle dependence, apoptosis effects, and adenosine release create a layered translational system. This article connects mechanism, protocol design, and biomimetic permeability methods to improve experimental interpretation and model selection.
-
Ziprasidone HCl Solid Dispersion and Food Effect
2026-09-12
The reference study developed a solvent-free hot-melt extrusion formulation combining Plasdone-S630 and HPMCAS-HF to improve ziprasidone hydrochloride dissolution and oral exposure. In beagle dogs, the optimized solid dispersion increased fasted-state exposure relative to Zeldox® and produced no significant fasted-versus-fed pharmacokinetic difference, supporting a formulation-based strategy for reducing food dependence.
-
740 Y-P as a PI3K Pathway Logic Probe
2026-09-11
740 Y-P is a cell-permeable PI 3-kinase activator for testing PI3K/AKT pathway causality. This guide connects pathway-direction experiments with vesicular trafficking research, cancer research, neuronal cell survival, and insights from oxidative-stress studies.
-
Lipid-Like Nanoassemblies for Secreted ACE2 mRNA
2026-09-11
The 2021 Advanced Materials study developed optimized binary lipid-like nanoassemblies that protected in-vitro-transcribed mRNA, promoted sustained protein production, and enabled efficient delivery in mice. When loaded with mRNA encoding high-affinity truncated ACE2 variants, the system generated secreted receptor decoys that blocked SARS-CoV-2 receptor-binding-domain interactions in vitro, illustrating a platform strategy for extracellular protein replacement.